About GEn1E
GEn1E is a Healthcare company based in Palo Alto (United States) founded in 2018 by Ritu Lal. Developer of therapeutics for the treatment of inflammatory and rare diseases. GEn1E has raised $22.67 million across 4 funding rounds from investors including Clear Ventures and Y Combinator. Its chief executive, as recorded, is Ritu Lal. GEn1E offers products and services including GEn-1124, p38Ξ±:MK2 Dual Signal Modulators, and NextGen ERK 1/2 Modulators. Its focus areas include Life Sciences, Immunology, Drugs and Inflammatory Diseases. Its competitors include Moderna, BridgeBio and Spark Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2018 and based in Palo Alto, United States, therapeutics for inflammatory and rare diseases are developed through an AI-driven platform. Multiple mechanisms of action in protein targets are addressed to advance novel therapies. The lead candidate, GEn-1124, targets chronic lung conditions, while other molecules remain in research and discovery phases within the biotechnology sector.
- Total Equity Funding$22.67M (USD)
in 4 rounds
- Latest Funding Round$5.52M (USD), Series A
Oct 2025
- InvestorsClear Ventures
& 1 more
Products & Services of GEn1E
GEn1E offers a comprehensive portfolio of products and services, including GEn-1124, p38α:MK2 Dual Signal Modulators, and NextGen ERK 1/2 Modulators.
Dual signal modulator for treating ARDS and inflammation.
Chronic oral treatment for inflammatory diseases.
Modulators targeting kinase dysregulation in diseases.
Funding Insights of GEn1E
GEn1E has successfully raised a total of $22.67M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $5.52 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $22.67M
- Total Rounds 4
- Last Round Series A β $5.52M
- First Round $125,000
(Aug 2019)
- Investors Count 2
All 4 funding rounds of GEn1E with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2025 | $5.52M | Series A | β | β | β |
| Dec 2022 | $17.03M | Series A | β | β | β |
| Jun 2021 | Seed | β | Clear Ventures | β | |
| Aug 2019 | $125,000 | Seed | β | β |
2 investors in total: 2 institutional.
Investors in GEn1E
GEn1E has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Clear Ventures and Y Combinator.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Tech focused early stage VC firm investing in the US, Europe, Asia | clear.ventures | Palo Alto, United States | ||
Early-stage startups are accelerated via funding and educational programs. | ycombinator.com | Mountain View, United States |
Investor details for GEn1E
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of GEn1E
10 people are tracked at GEn1E (4 in leadership, 5 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
Ritu Lal | Co-Founder & CEO | Leadership |
Ritu Lal Ph.d. (Management) | CEO And Co-founder | Leadership |
Wendy Luo | VP, Research | Leadership |
Beth Stannard, MS, CCRP, CCRC | Head Of Clinical Operations | Leadership |
Ijlal Babar | Advisor | Board & advisors |
David Young | Advisor | Board & advisors |
Alan J. Levy | Advisor | Board & advisors |
Leonard Hayflick | Advisor | Board & advisors |
Robert Booth | Advisor | Board & advisors |
Rishabh Goel | Advisor | Team |
Complete people profiles for GEn1E
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of GEn1E
3 dated milestones of GEn1E across 7 years, from founding to its latest funding, stage changes and deals.
- Founded GEn1E is founded.
- Funding First funding round of $125K.
- Funding Latest funding round, Series A, of $5.5M.
Competitors of GEn1E
GEn1E has 3 listed competitors in our database, 3 of them funded. They include Moderna, BridgeBio and Spark Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. |
Detailed competitors of GEn1E
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as GEn1E (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Gen1e
Complete news archive for GEn1E
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GEn1E
GEn1E was founded in 2018 and raised its 1st funding round 1 year after it was founded.
GEn1E is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Ritu Lal is the CEO of GEn1E, as recorded in our data. They have also founded this company.
GEn1E is a funded company, having raised a total of $22.67M across 4 funding rounds to date. The company's 1st funding round was a Seed of $125K, raised on Aug 2019.
Founded in 2018 and based in Palo Alto, United States, therapeutics for inflammatory and rare diseases are developed through an AI-driven platform. Multiple mechanisms of action in protein targets are addressed to advance novel therapies. The lead candidate, GEn-1124, targets chronic lung conditions, while other molecules remain in research and discovery phases within the biotechnology sector.
GEn1E's top competitors include Moderna, Spark Therapeutics and BridgeBio.
GEn1E offers GEn-1124, p38Ξ±:MK2 Dual Signal Modulators, and NextGen ERK 1/2 Modulators.
GEn1E has 2 investors. Key investors include Clear Ventures, and Y Combinator.